DOCSLIB.ORG

2021 National Veterinary Scholars Symposium

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2021 National Veterinary Scholars Symposium 2021 National Veterinary Scholars Symposium Contents Welcome ................................................................................................ 1 Program Schedule ................................................................................ 2 Speaker Biographies ............................................................................. 4 Award Winners ..................................................................................... 6 Abstracts Listed by Area of Research ................................................ 8 Symposium Participants by College of Veterinary Medicine ..........36 Complete Abstracts (listed alphabetically) ......................................51 Welcome Welcome to the 2021 National Veterinary Summer Scholars Symposium, hosted by Iowa State University’s College of Veterinary Medicine! Even though you are joining us for this year’s symposium virtually and won’t be able to tour the nation’s first public veterinary college, I know our programming committee has put together an excellent and challenging series of sessions, keynotes and other activities for you. The NVSSS has long been the premier annual scientific gathering where veterinary students like yourself can showcase the many research accomplishments you have achieved this summer. The symposium will once again highlight the many different ways veterinary scientists advance basic and applied research to support global animal and human health. The essence of research is to inform action. For all of us that are involved in research, our ultimate hope is that our find- ings leads to actions that positively impacts society, no matter how small or large. Without action, there is really know purpose for research. I challenge to think about your research findings from this summer and how they someday will inform actions that make a difference. I hope your summer scholars experience was engaging and challenging. I know you join me in anticipating and learning from the research each of you conducted. Enjoy the symposium! Dan Grooms DVM, PhD Dr. Steven G. Juelsgaard Dean of Veterinary Medicine Boehringer Ingelheim is delighted to continue our long-standing support of veterinary research by sponsoring this National Veterinary Scholars Symposium that will enable veterinary students and young researchers to share the results of their summer research, and we especially welcome this year’s Boehringer Ingelheim Veterinary Scholars. Now more than ever we realize the importance of developing and nurturing scientists with the skills and training to fulfill our needs for comparative animal research, animal and human food safety, and drug development if we are to continue to advance biomedical research. Eric Haaksma, Head of Animal Health Global Innovation, Boehringer Ingelheim The AAVMC is proud to partner with Iowa State University on the presentation of the 2021 National Veterinary Scholars Symposium. Scientific explorations and advancements in the body of knowledge are more important than ever before as we face the impending disease and food security threats of the future, and veterinary medicine must play a role at the heart of that effort. This program encourages our students to gain experience, develop their skills and consider careers in this vital area of our profession. It also celebrates and illuminates the success of the important work they have accom- plished. The AAVMC is honored to be a part of it.” Andy MacCabe, CEO, American Association of Veterinary Medical Colleges 2021 National Veterinary Scholars Symposium • 1 2021 NVSS Program Schedule Wednesday, August 4 TIME Moderator: Yuko Sato, DVM, MS, Diplomate ACPV (Eastern Daylight Time) Assistant Professor at Iowa State University 11.30 AM – 11.40 AM Welcome Videos Dean Dan Grooms at Iowa State University and Boehringer Ingelheim 11.45 AM – 12.45 PM Poster Session 1 1.00 PM – 2.00 PM Keynote: Kathryn Marie Jones, DVM, PhD Associate Professor at Baylor College of Medicine, Houston TX “Addressing the Global Burden of Chagas Disease” 02.15 PM – 2.45 PM Boehringer Ingelheim Networking Session Leaning into Opportunities for Personal Development and Building your Network 3:00 PM – 4.00 PM Poster Session 2 4:15 PM – 4.45 PM Meet the Experts I – Breakout Sessions Career advice from veterinarians who work in: . • Academia . • Government . • Industry 2 • 2021 National Veterinary Scholars Symposium Thursday, August 5 TIME Debora Brito Goulart, BVetMed, MSc (Eastern Daylight Time) PhD student at Iowa State University 11.30 AM – 11.40 AM Welcome Videos Boehringer Ingelheim and the College of Veterinary Medicine at Iowa State University 11.45 AM – 12.45 PM Poster Session 3 1.00 PM – 2.00 PM Keynote: Jim Roth, DVM, MS, PhD, Diplomate ACVM Distinguished Professor at Iowa State University, Ames IA “Infectious Disease Control through Research, Policy Development, and Education” 02.15 PM – 2.45 PM Awards Presentation AVMA Excellence in Research Awards and Boehringer Ingelheim Veterinary Research Awards for Graduate Veterinarians and Veterinary Students 3:00 PM – 4.00 PM Poster Session 4 4:15 PM – 4.45 PM Meet the Experts II – Breakout Sessions Which degree should I get? Career advice from: • DVM/PhD Researchers • DVM/MSc Researchers • DVM Clinician Research Scientists without an Advanced Research Degree Friday, August 6 TIME Moderator: Olufemi Fasina, DVM, PhD, Diplomate ACVP (Eastern Daylight Time) Assistant Professor at Iowa State University 11.30 AM – 11.40 AM Final Remarks and Boehringer Ingelheim Video Presentation 11.45 AM – 12.45 PM Poster Session 5 1.00 PM – 2.00 PM Keynote: Liara Gonzalez, DVM, PhD, DAVS Associate Professor at North Carolina State University, Raleigh, NC “Intestinal Regenerative Medicine: Targeting Key Stem Cells to Enhance Intestinal Viability” 02.15 PM – 2.45 PM Meet the Experts III – Breakout Sessions Career advice from veterinarians with research programs that focus on: • Companion Animals . • Equines . • Production Animals 3:00 PM – 4.00 PM Poster Session 6 4:15 PM – 4.45 PM Meet the Experts IV – Breakout Sessions Career advice from veterinarians with research programs that focus on: • Pathogens and Vaccine Development . • Veterinary Epidemiology . • Diagnostic Pathology 2021 National Veterinary Scholars Symposium • 3 Keynote Speakers Kathryn M. Jones, DVM, PhD Associate Professor Baylor College of Medicine Presentation title & date: Addressing the Global Burden of Chagas Disease Wednesday, August 4 from 1.00 – 2.00pm EDT Bio: Kathryn Jones is an Associate Professor in the Departments of Pediatrics, Section of Tropical Medicine, and Molecular Virology and Microbiology at Baylor College of Medicine. She is also the Director of the Pre-Clinical Testing Unit at the Texas Children’s Hospital Cen- ter for Vaccine Development, and the Technical Lead for the Chagas Vaccine Initiative. Dr. Jones received both her Doctor of Veterinary Medicine and PhD from Michigan State University. Dr. Jones’ current research projects focus on understanding mechanisms of inflamma- tion and fibrosis caused by Trypanosoma cruzi, the parasite responsi- ble for Chagas disease, and developing novel immunotherapies. Jim Roth, DVM, PhD Distinguished Professor Iowa State University Presentation title & date: Infectious disease control through research, policy development, and education Thursday, August 5 from 1.00 – 2.00pm EDT Bio: Jim Roth is a Distinguished Professor in the College of Veterinary Medicine at Iowa State University and a member of the National Academy of Medicine. He received the DVM and PhD (immunology) degrees from ISU. He is the Director of the Center for Food Securi- ty and Public Health and the Institute for International Cooperation in Animal Biologics. Dr. Roth’s primary area of research expertise is immunity to infectious diseases of food producing animals. He has testified before Congressional committees on biosecurity preparedness, on efforts to address bioterrorism and agroterrorism, and on the need for vaccines for foreign animal diseases. Dr. Roth served on the National Science Advisory Board for Biosecurity from 2005 to 2014. 4 • 2021 National Veterinary Scholars Symposium Liara M. Gonzalez, DVM, PhD Associate Professor NC State University Presentation Title and date: Intestinal Regenerative Medicine: Targeting Key Stem Cells to Enhance Intestinal Viability Friday, August 6, 1:00 – 2:00 EDT Bio: Dr. Liara Gonzalez is an Associate Professor of Gastroenterology and Equine Surgery at North Carolina State University in Raleigh, NC. She received her veterinary degree from Cornell University College of Veterinary Medicine in 2006, completed a large animal surgery residency at NC State Veterinary Hospital and became a Diplomate of the American College of Veterinary Surgery in 2011. She remained at NC State and defended her doctoral thesis in 2014. Dr. Gonzalez’ clinical and research focus is on intestinal disease, with a particular interest in identifying improved means to determine tissue viability following severe intestinal injury as well as studying the role of intestinal stem cells in modulating mucosal barrier repair following isch- emic damage. Dr. Gonzalez hopes to apply her knowledge and expertise in advanced laboratory techniques to help solve clinically significant problems and further elucidate therapeutic targets that will ultimately improve patient survival. 2021 National Veterinary Scholars Symposium • 5 Award Winners AVMA Excellence in Research Award Recipients 2021 The AVMA is proud to recognize veterinarians and scientists for their outstanding contributions
Load more

Recommended publications
  • Isbn 978-625-409-353-1
    ISBN 978-625-409-353-1 INTERNATIONAL CONGRESS ON BIOLOGICAL AND HEALTH SCIENCES PROCEEDİNGS BOOK This work is subject to copyright and all rights reserved, whether the whole or part of the material is concerned. The right to publish this book belongs to International Congress on Biological and Health Sciences-2021. No part of this publication may be translated, reproduced, stored in a computerized system, or transmitted in any form or by any means, including, but not limited to electronic, mechanical, photocopying, recording without written permission from the publisher. This Proceedings Book has been published as an electronic publication (e-book). The publisher is not responsible for possible damages, which may be a result of content derived from this electronic publication All authors are responsible for the contents of their abstracts. https://www.biohealthcongress.com/ ([email protected]) Editor Ulaş ACARÖZ Published: 28/03/2021 ISBN: Editor's Note The first ‘International Congress on Biological and Health Sciences’ was organized online and free of charge. We are very happy and proud that various health science-related fields attended the congress. By this event, the distinguished and respected scientists came together to exchange ideas, develop and implement new researches and joint projects. There were 15 invited speakers from 10 different countries and also approximately 400 submissions were accepted from more than 20 countries. We would like to thank all participants and supporters. Hope to see you at our next congress.
    [Show full text]
  • (Public Pack)Agenda Document for Licensing Committee, 05/12/2017 10:00
    Public Document Pack LICENSING COMMITTEE MEETING TO BE HELD IN CIVIC HALL, LEEDS ON TUESDAY, 5TH DECEMBER, 2017 AT 10.00 AM MEMBERSHIP Councillors N Buckley Alwoodley; R Downes Otley and Yeadon; J Dunn Ardsley and Robin Hood; B Flynn Adel and Wharfedale; B Gettings Morley North; M Harland Kippax and Methley; G Hyde Killingbeck and Seacroft; A Khan Burmantofts and Richmond Hill; B Selby (Chair) Killingbeck and Seacroft; C Townsley Horsforth; G Wilkinson Wetherby; A Garthwaite Headingley; K Groves Middleton Park; S McKenna Garforth and Swillington; J Pryor Headingley; Agenda compiled by: John Grieve Tel No: (0113) 37 88662 Governance Services Civic Hall LEEDS LS1 1UR Produced on Recycled Paper A A G E N D A Item Ward/Equal Item Not Page No Opportunities Open No 1 APPEALS AGAINST REFUSAL OF INSPECTION OF DOCUMENTS To consider any appeals in accordance with Procedure Rule 15.2 of the Access to Information Procedure Rules (in the event of an Appeal the press and public will be excluded) (*In accordance with Procedure Rule 15.2, written notice of an appeal must be received by the Head of Governance Services at least 24 hours before the meeting) 2 EXEMPT INFORMATION - POSSIBLE EXCLUSION OF THE PRESS AND PUBLIC 1 To highlight reports or appendices which officers have identified as containing exempt information, and where officers consider that the public interest in maintaining the exemption outweighs the public interest in disclosing the information, for the reasons outlined in the report. 2 To consider whether or not to accept the officers recommendation in respect of the above information.
    [Show full text]
  • Contributions to the 12Th Conference of the European Wildlife Disease Association (EWDA) August 27Th – 31St, 2016, Berlin
    12th Conference of the European Wildlife Disease Association (EWDA), Berlin 2016 Contributions to the 12th Conference of the European Wildlife Disease Association (EWDA) August 27th – 31st, 2016, Berlin, Germany Edited by Anke Schumann, Gudrun Wibbelt, Alex D. Greenwood, Heribert Hofer Organised by Leibniz Institute for Zoo and Wildlife Research (IZW) Alfred-Kowalke-Straße 17 10315 Berlin Germany www.izw-berlin.de and the European Wildlife Disease Association (EWDA) https://sites.google.com/site/ewdawebsite/ & ISBN 978-3-9815637-3-3 12th Conference of the European Wildlife Disease Association (EWDA), Berlin 2016 Published by Leibniz Institute for Zoo and Wildlife Research (IZW) Alfred-Kowalke-Str. 17, 10315 Berlin (Friedrichsfelde) PO Box 700430, 10324 Berlin, Germany Supported by Deutsche Forschungsgemeinschaft (DFG) [German Research Foundation] Kennedyallee 40, 53175 Bonn, Germany Printed on Forest Stewardship Council certified paper All rights reserved, particularly those for translation into other languages. It is not permitted to reproduce any part of this book by photocopy, microfilm, internet or any other means without written permission of the IZW. The use of product names, trade names or other registered entities in this book does not justify the assumption that these can be freely used by everyone. They may represent registered trademarks or other legal entities even if they are not marked as such. Processing of abstracts: Anke Schumann, Gudrun Wibbelt Setting and layout: Anke Schumann, Gudrun Wibbelt Cover: Diego Romero, Steven Seet, Gudrun Wibbelt Word cloud: ©Tagul.com Printing: Spree Druck Berlin GmbH www.spreedruck.de Order: Leibniz Institute for Zoo and Wildlife Research (IZW) Forschungsverbund Berlin e.V. PO Box 700430, 10324 Berlin, Germany [email protected] www.izw-berlin.de 12th Conference of the European Wildlife Disease Association (EWDA), Berlin 2016 CONTENTS Foreword .................................................................................................................
    [Show full text]
  • Guidelines for Pain and Distress in Laboratory Animals: Responsibilities, Recognition, and Intervention
    Guidelines for Pain and Distress in Laboratory Animals: Responsibilities, Recognition, and Intervention Introduction Animals can experience pain and distress. It is the ethical and legal obligation of all personnel involved with the use of animals in research to reduce or eliminate pain and distress in research animals whenever such actions do not interfere with the research objectives. The Institute/Center Animal Care and Use Committee (IC ACUC) has the delegated responsibility and accountability for ensuring that all animals under their oversight are used humanely and in accordance with a number of Federal Regulations and policies.2,21,29,30,32 Key to fulfilling the responsibilities for both the Principal Investigator (PI) and the IC ACUC are to: • understand the legal requirements, • be able to distinguish pain and distress in animals from their normal state, • relieve or minimize the pain and distress appropriately; and • establish humane endpoints. Regulatory Requirements and IC ACUC Responsibilities The IC ACUC must ensure that all aspects of the animal study proposal (ASP) that may cause more than transient pain and/or distress are addressed; alternatives6 to painful or distressful procedures are considered; that methods, anesthetics, and analgesics to minimize or eliminate pain and distress are included when these methods do not interfere with the research objectives; and that humane endpoints have been established for all situations where more than transient pain and distress can not be avoided or eliminated. Whenever possible, death or severe pain and distress should be avoided as endpoints. A written scientific justification is required to be included in the ASP for any more than transient painful or distressful procedure that cannot be relieved or minimized.
    [Show full text]
  • Examining the Antimicrobial Activity of Cefepime-Taniborbactam
    Examining the antimicrobial activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States Elise T. Zeiser1, Scott A. Becka1, John J. LiPuma2, David A. Six 3, Greg Moeck 3, and Krisztina M. Papp-Wallace1,4 1Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH; 2University of Michigan, Ann Arbor, MI; 3Venatorx 4 Pharmaceuticals, Inc., Malvern, PA; and Case Western Reserve University, Cleveland, OH Correspondence to: [email protected] Abstract Results Background: Burkholderia cepacia complex (Bcc), a group of >20 related species, and B. gladioli are 60 opportunistic human pathogens that cause chronic infections in people with cystic fibrosis (CF) or cefepime compromised immune systems. Ceftazidime and trimethoprim-sulfamethoxazole are first-line agents used to treat infections due to Burkholderia spp. However, these species have developed resistance to cefepime-taniborbactam many antibiotics, including first-line therapies. β-lactam resistance in Burkholderia species is largely 40 mediated by PenA-like chromosomal class A β-lactamases. A novel investigational β-lactam/β-lactamase inhibitor combination, cefepime-taniborbactam (formerly cefepime/VNRX-5133) demonstrates potent antimicrobial activity against gram-negative bacteria producing class A, B, C, and D β-lactamases. The activity of cefepime-taniborbactam was investigated against Bcc and B. gladioli; moreover, the biochemical activity of taniborbactam against the PenA1 carbapenemase was evaluated. 20 Methods: CLSI-based agar dilution antimicrobial susceptibility testing using cefepime and cefepime combined with taniborbactam at 4 mg/L was conducted against a curated panel of 150 Burkholderia species obtained from the Burkholderia cepacia Research Laboratory and Repository. Isolates were Number isolates of recovered from respiratory specimens from 150 different individuals with CF receiving care in 68 cities 0 throughout 36 states within the United States.
    [Show full text]
  • Volume 37 Number 10
    VOLUME 37 NUMBER 10 NOVEMBER 2019 Gates Foundation Plots A Fresh Metric From US To EU: Young Biotechs Early Dialogue: Getting The Most For Market Access: Lives Saved Going It Alone Out Of Advice From HTA Agencies PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ November 2019 MARKET ACCESS Balancing benefit and value against health care sustainability 10 16 22 In US Drug Pricing Debate, Market Access 2020: Gates Foundation Plots A ICER’s Voice Gets Louder Understanding US Payer Fresh Metric For Market Access: MELANIE SENIOR Expectations Lives Saved The Institute for Clinical and Economic WILLIAM LOONEY WILLIAM LOONEY Review's influence on drug pricing, and Big pharma is facing a difficult US In Vivo visits Gates Medical Research policy, is growing. Spotlighting the worst competitive landscape as its traditional Institute CEO Dr. Penny Heaton to review its drug price rises is one recent example. customers realign to build their own first pipeline of drugs and vaccines to Ten years ago, it would have seemed redoubts of size, scale and reach. attack four of the world’s biggest killers: unthinkable that an independent, Consolidation on the payer side is TB, malaria, enteric diseases and other non-profit organization with no statutory changing the dynamics of success in conditions affecting maternal, newborn power could influence the pricing health care. and child health, as well as highlight the behavior of the US pharmaceutical sector. unique business model of this latest Yet that is what ICER has achieved. 36 addition to the Bill & Melinda Gates Foundation and reveal more about the From US To EU: focus and aims of the Boston, US group.
    [Show full text]
  • Table S4. Phylogenetic Distribution of Bacterial and Archaea Genomes in Groups A, B, C, D, and X
    Table S4. Phylogenetic distribution of bacterial and archaea genomes in groups A, B, C, D, and X. Group A a: Total number of genomes in the taxon b: Number of group A genomes in the taxon c: Percentage of group A genomes in the taxon a b c cellular organisms 5007 2974 59.4 |__ Bacteria 4769 2935 61.5 | |__ Proteobacteria 1854 1570 84.7 | | |__ Gammaproteobacteria 711 631 88.7 | | | |__ Enterobacterales 112 97 86.6 | | | | |__ Enterobacteriaceae 41 32 78.0 | | | | | |__ unclassified Enterobacteriaceae 13 7 53.8 | | | | |__ Erwiniaceae 30 28 93.3 | | | | | |__ Erwinia 10 10 100.0 | | | | | |__ Buchnera 8 8 100.0 | | | | | | |__ Buchnera aphidicola 8 8 100.0 | | | | | |__ Pantoea 8 8 100.0 | | | | |__ Yersiniaceae 14 14 100.0 | | | | | |__ Serratia 8 8 100.0 | | | | |__ Morganellaceae 13 10 76.9 | | | | |__ Pectobacteriaceae 8 8 100.0 | | | |__ Alteromonadales 94 94 100.0 | | | | |__ Alteromonadaceae 34 34 100.0 | | | | | |__ Marinobacter 12 12 100.0 | | | | |__ Shewanellaceae 17 17 100.0 | | | | | |__ Shewanella 17 17 100.0 | | | | |__ Pseudoalteromonadaceae 16 16 100.0 | | | | | |__ Pseudoalteromonas 15 15 100.0 | | | | |__ Idiomarinaceae 9 9 100.0 | | | | | |__ Idiomarina 9 9 100.0 | | | | |__ Colwelliaceae 6 6 100.0 | | | |__ Pseudomonadales 81 81 100.0 | | | | |__ Moraxellaceae 41 41 100.0 | | | | | |__ Acinetobacter 25 25 100.0 | | | | | |__ Psychrobacter 8 8 100.0 | | | | | |__ Moraxella 6 6 100.0 | | | | |__ Pseudomonadaceae 40 40 100.0 | | | | | |__ Pseudomonas 38 38 100.0 | | | |__ Oceanospirillales 73 72 98.6 | | | | |__ Oceanospirillaceae
    [Show full text]
  • Do “Prey Species” Hide Their Pain? Implications for Ethical Care and Use of Laboratory Animals
    Journal of Applied Animal Ethics Research 2 (2020) 216–236 brill.com/jaae Do “Prey Species” Hide Their Pain? Implications for Ethical Care and Use of Laboratory Animals Larry Carbone Independent scholar; 351 Buena Vista Ave #703E, San Francisco, CA 94117, USA [email protected] Abstract Accurate pain evaluation is essential for ethical review of laboratory animal use. Warnings that “prey species hide their pain,” encourage careful accurate pain assess- ment. In this article, I review relevant literature on prey species’ pain manifestation through the lens of the applied ethics of animal welfare oversight. If dogs are the spe- cies whose pain is most reliably diagnosed, I argue that it is not their diet as predator or prey but rather because dogs and humans can develop trusting relationships and because people invest time and effort in canine pain diagnosis. Pain diagnosis for all animals may improve when humans foster a trusting relationship with animals and invest time into multimodal pain evaluations. Where this is not practical, as with large cohorts of laboratory mice, committees must regard with skepticism assurances that animals “appear” pain-free on experiments, requiring thorough literature searches and sophisticated pain assessments during pilot work. Keywords laboratory animal ‒ pain ‒ animal welfare ‒ ethics ‒ animal behavior 1 Introduction As a veterinarian with an interest in laboratory animal pain management, I have read articles and reviewed manuscripts on how to diagnose a mouse in pain. The challenge, some authors warn, is that mice and other “prey species” © LARRY CARBONE, 2020 | doi:10.1163/25889567-bja10001 This is an open access article distributed under the terms of the CC BY 4.0Downloaded license.
    [Show full text]
  • Scientific Advances in the Study of Animal Welfare
    Scientific advances in the study of animal welfare How we can more effectively Why Pain? assess pain… Matt Leach To recognise it, you need to define it… ‘Pain is an unpleasant sensory & emotional experience associated with actual or potential tissue damage’ IASP 1979 As it is the emotional component that is critical for our welfare, the same will be true for animals Therefore we need indices that reflect this component! Q. How do we assess experience? • As it is subjective, direct assessment is difficult.. • Unlike in humans we do not have a gold standard – i.e. Self-report – Animals cannot meaningfully communicate with us… • So we traditionally use proxy indices Derived from inferential reasoning Infer presence of pain in animals from behavioural, anatomical, physiological & biochemical similarity to humans In humans, if pain induces a change & that change is prevented by pain relief, then it is used to assess pain If the same occurs in animals, then we assume that they can be used to assess pain Quantitative sensory testing • Application of standardised noxious stimuli to induce a reflex response – Mechanical, thermal or electrical… – Used to measure nociceptive (i.e. sensory) thresholds • Wide range of methods used – Choice depends on type of pain (acute / chronic) modeled • Elicits specific behavioural response (e.g. withdrawal) – Latency & frequency of response routinely measured – Intensity of stimulus required to elicit a response • Easy to use, but difficult to master… Value? • What do these tests tell us: – Fundamental nociceptive mechanisms & central processing – It measures evoked pain, not spontaneous pain • Tests of hypersensitivity not pain per se (Different mechanisms) • What don’t these tests tell us: – Much about the emotional component of pain • Measures nociceptive (sensory) thresholds based on autonomic responses (e.g.
    [Show full text]
  • Administrative-Professional Association
    ssociation COLLECTIVE BARGAINING AGREEMENT A Between MICHIGAN STATE UNIVERSITY and rofessional MICHIGAN STATE UNIVERSITY ADMINISTRATIVE-PROFESSIONAL P ASSOCIATION October 1, 2015 – September 30, 2019 dministrative A TABLE OF CONTENTS PURPOSE AND INTENT 3 ARTICLE 1 RECOGNITION 4 ARTICLE 2 MANAGEMENT'S RIGHTS 5 ARTICLE 3 MANAGEMENT SECURITY 6 ARTICLE 4 AID TO OTHER LABOR UNIONS 7 ARTICLE 5 ASSOCIATION MEMBERSHIP 8 ARTICLE 6 ASSOCIATION RIGHTS 10 ARTICLE 7 EMPLOYMENT STATUS 13 ARTICLE 8 PROBATIONARY/TRIAL PERIOD 17 ARTICLE 9 SENIORITY 19 ARTICLE 10 SETTLEMENT OF DISPUTES 20 ARTICLE 11 OFFICIAL PERSONNEL FOLDERS 25 ARTICLE 12 PERFORMANCE EVALUATIONS 26 ARTICLE 13 PROMOTION/DEMOTION 27 ARTICLE 14 FILLING VACANT POSITIONS 28 ARTICLE 15 CLASSIFICATION/RECLASSIFICATION OF POSITIONS 29 ARTICLE 16 REDUCTION IN FORCE 30 ARTICLE 17 COMPENSATION PROGRAMS 43 ARTICLE 18 SPECIAL PROVISIONS 47 ARTICLE 19 LEAVE OF ABSENCE WITH PAY 49 ARTICLE 20 LEAVES OF ABSENCE WITHOUT PAY 50 ARTICLE 21 VACATION PAY 52 ARTICLE 22 PERSONAL LEAVE DAYS 54 ARTICLE 23 HOLIDAYS 55 ARTICLE 24 SICK LEAVE 56 ARTICLE 25 MILITARY LEAVE OF ABSENCE 59 ARTICLE 26 MATERNITY LEAVE 60 ARTICLE 27 FLEXIBLE APPOINTMENTS 61 ARTICLE 28 LONGEVITY PAY 66 ARTICLE 29 JURY DUTY PAY 67 ARTICLE 30 MILITARY DUTY PAY 68 ARTICLE 31 BEREAVEMENT DAYS 69 ARTICLE 32 OVERVIEW 70 ARTICLE 33 RETIREE/OVER 65 LIFE PROGRAM 72 ARTICLE 34 ACCIDENTAL DEATH AND DISMEMBERMENT PROGRAM 73 ARTICLE 35 DENTAL PLAN 74 ARTICLE 36 EMPLOYEE PAID LIFE PLAN 75 ARTICLE 37 EXTENDED DISABILITY LEAVE 76 ARTICLE 38 EXPANDED LIFE
    [Show full text]
  • A Vision for Success
    MICHIGAN STATE UNIVERSITY ALUMNI MAGAZINE FALL 2017 MORE PROFILES A Vision INSIDE ERIK for Success QUALMAN MANOJ How entrepreneurial SAXENA Spartans turn their ALEXA ideas into reality JONES THE #1 CARD FOR SPARTAN FANS cash 1% back MSUFCU'sMSUFCU's PlatinumPlatinum PlusPlus VisaVisa offersoffers yyou:ou: Cash Back — Earn unlimited 1% cash back on allall purchasespurchases Redeem your way — The freedom to redeem instantly,instantly, forfor aanyny aamountmount No annual, application, or balance transfer fees — "No""No" hashas nevernever soundedsounded soso nniceice APPLYAPPLY TODAY! mmsufcu.org/cashbacksufcu.org/cashback • 8800-678-496800-678-4968 MembersMembers willwill earnearn 1%1% cashcash backback onon allall purchases.purchases. CashCash backback isis notnot earnedearned onon taxtax payments,payments, anyany unauthorizedunauthorized chargescharges oorr ttransactions,ransactions, ccashash aadvances,dvances, cconvenienceonvenience cchecks,hecks, bbalancealance ttransfers,ransfers, oorr ffeesees ooff aanyny kkind.ind. VVisitisit mmsufcu.org/cashbacksufcu.org/cashback for full terms and conditions. Federally insured by NCUA. FALL 2017 26 An Insider’s Guide to Entrepreneurship Follow our experts, students, and alumni as they nurture, launch, lead, and grow their ploys into marketable products and services. 18 Inventive Spartans Meet a trio of ingenious alumni shaking things up in the entrepreneurial ecosystem. 47 9 Spartans Connect and Inspire DEPARTMENTS Follow MSUAA Director Scott Westerman 3 FROM THE PRESIDENT and catch up on alumni news. Celebrate the 5 LETTERS TO THE EDITOR MSU Black Alumni Association’s Scholarship 9 BENEATH THE PINES endowment, peruse photos from Spartans 52 DONOR SOCIETIES around the world, and more. 61 CLASS NOTES 67 IN MEMORIAM 80 FROM THESE SCENES ON THE COVER Erik Qualman, also known as Equalman, poses in his green Clark-Kent-style glasses, a signature look for his personal brand.
    [Show full text]
  • Media Documentation Incl
    Media Documentation incl. Line-up Session Basel AG, Grenzacherstrasse 79, 4058 Basel BALOISE SESSION 2016 21 October - 8 November 2016 _________________________________________________________________________________ Contents Page Long media text 3 Short media text 6 Fairwell Matthias 7 Concerts and Admission Prices 8 Advance Ticket Sales 9 Artist Photos 9 Contact BALOISE SESSION 9 Social Media 9 Sponsors / Media Partners 10 Emeli Sandé / Joris 11 Jeff Beck / Sivert Høyem 13 Alvaro Soler / Rodrigo y Gabriela 15 Seven / Laura Mvula 17 Culture Club / Parov Stelar 19 John Newman / Milow 21 Brian Wilson / Donavon Frankenreiter 23 Kaiser Chiefs / Boy 25 Marcus Miller / Stacey Kent 27 Kenny Rogers / Brandi Carlile 29 Norah Jones / Damian Lynn 31 Silbermond / Max Jury 33 Session Basel AG 21 October 2016 2 BALOISE SESSION 2016 21 October - 8 November 2016 _________________________________________________________________________________ Long media text BALOISE SESSION 2016 – 24 musical highlights in an intimate, candlelight club atmosphere From 21 October to 8 November it's time again for the 31st BALOISE SESSION. In a series of 12 concerts 24 world-famous acts and exciting newcomers will be appearing on stage in the unique intimate club-like setting with candlelight and small tables. The programme includes the finest soul-pop from Emeli Sandé, blues-rock from Jeff Beck, Latin-pop by Alvaro Soler, soul by Seven and country from Kenny Rogers. The future of the popular music festival is assured: Baloise Insurance has ex- tended its partnership as Presenting Sponsor until 2020. A positive signal in a difficult year marked by a major loss: last July festival founder and President Matthias Müller died at the age of 51 after a serious illness.
    [Show full text]